Allogene Therapeutics
Kristen Zhang currently serves as a Scientist at Allogene Therapeutics, a role held since May 2021, after progressing from Senior Associate Scientist. Prior experience includes a tenure at Arcus Biosciences from October 2016 to April 2021, where Kristen held positions ranging from Research Associate I to Senior Research Associate. Additionally, Kristen worked as a Quality Control Associate at Biocheck, Inc. from August 2015 to September 2016. Kristen holds a Bachelor of Science degree in Cell and Molecular Biology from San Francisco State University.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.